89bio's Pegozafermin Data Shows Improved Liver Fat, Glycemic Control

89bio Inc ETNB announced the presentation of data from the ENTRIGUE Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia (SHTG) at the European Society of Cardiology Congress.
Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, increasing the risk of coronary artery disease.
Pegozafermin met its primary endpoint of statistically significant reductions in median triglycerides (TGs) from baseline across all dose groups compared to placebo after eight weeks.
Related: This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations.
A sub-study of treated patients showed robust reductions in liver fat from baseline at week eight across all dose groups versus placebo.
Further, 88% of treated patients vs. 0% of placebo patients achieved a ≥30% reduction in liver fat from baseline, and 24% of treated patients vs. 0% of placebo patients achieved normalized liver fat levels at week 8.
Pegozafermin treatment also resulted in clinically meaningful improvements in non-HDL-C and apo-B, a key marker of cardiovascular risk and a direct measure of the number of atherogenic particles.
Pegozafermin is currently being evaluated in the Phase 2b ENLIVEN trial in NASH and is expected to move into the Phase 3 program for SHTG in 2023.
Price Action: ETNB shares are up 7.61% at $5.10 during the premarket session on the last check Friday.